Posters simples

• 1 • PS-001 - Medication reconciliation : interest of a « major accord » > J. Jean Doucet • 10 • PS-007 - QT prolongation and Vortioxetine: a post-marketing study > C. Constance Bordet • 101 • PS-048 - Cannabinoid-related acute pancreatitis. An update from international literature and individual case safety reports > M. Maryse Lapeyre-Mestre • 104 • PS-049 - Piperacillin-induced drug reaction with eosinophilia and systemic symptoms (DRESS): the largest case series > A. Aurore Gouraud • 108 • PS-050 - Drug use and pharmacovigilance: patients perspectives > J-L. Jean-Luc Faillie • 110 • PS-052 - 4’-Chlorodiazepam, a TSPO ligand, inhibits STAR translocation and mitochondrial cholesterol accumulation after myocardial ischemia-reperfusion. > S. Shirin Leick • 112 • PS-053 - Suspicion of fluindione-induced tracheobronchopathia osteochondroplastica > C. Caroline Joyau • 114 • PS-054 - Falsified prescriptions as an indicator of prescription drug diversion: Assessment in Occitanie Est between 2017 and 2020 > H. Hélène Peyriere • 117 • PS-055 - What are the additional ANSM/CPP requests concerning the clinical trials vigilance unit of Grenoble university hospital? > L. Laura Leo • 118 • PS-056 - Immune-checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer: observational retrospective study using the WHO pharmacovigilance database > C. Charles Dolladille • 119 • PS-057 - Anticancer drugs and the risk of cardiovascular-related hospitalization in metastatic colorectal cancer: Insights from the AVOCETTE registry study in the French county Calvados > C. Charles Dolladille • 12 • PS-008 - Opinion and interpretation of new « pregnancy » pharmaceutical pictograms > V. Valérie Gras-Champel • 122 • PS-058 - A sensitization campaign on under-reporting in Pharmacovigilance at the Faculty of Pharmacy > B. Brahim Azzouz • 123 • PS-059 - Isoniazid and Parkinson's disease treatment : interaction? > B. Brahim Azzouz • 125 • PS-060 - Assessment of serious adverse events reporting by investigational centers in academic clinical trials: cross-sectional survey and suggestions for improvement measures > P. Pascale Olivier • 127 • PS-061 - Gemcitabine-induced lightheadedness in a 57-year-old woman : case report of positive rechallenge > C. Clément Cholle • 128 • PS-062 - Impact of discharge medication reconciliation in Internal and Geriatric Medicine departments > J. Jean Doucet • 130 • PS-063 - Anti-BRAF molecules (ABM)-induced acute pancreatitis. Analyse of class-effect positive rechallenge from the French Pharmacovigilance Database (FPVD) > M. Marie Noelle Beyens • 131 • PS-064 - Characterization of pharmacodynamics interaction between oxycodone and diclazepam, a designer benzodiazepine, in mice > R. Roland Lawson • 132 • PS-065 - Analgesic prescribing in cancer outpatients during their last year of life in France: a longitudinal cohort study based on the French health insurance database > M. Maryse Lapeyre-Mestre • 133 • PS-066 - HOPIPRAC, PRAC signals validation sentinel system, from a hospital data warhouse > L. Layal El Aridi • 134 • PS-067 - A novel biased agonist of 5-HT1A receptors to treat Levodopa-induced dyskinesia ? Exploration of the antidyskinetic effects of NLX-112, using [18F]FDG-PET in hemiparkinsonian rats > S. Sarah CHAÏB • 138 • PS-068 - Is ferutinine a pharmacological tool to investigate mitochondrial permeability transition pore opening? > J. Juliette Bréhat • 140 • PS-069 - Tricytopenia after treatment by methotrexate and ciprofloxacin: an under recognized drug interaction > S. Serena Romani • 141 • PS-070 - Perception of generic drugs in Tunisian Doctors > S. Sameh Trabelsi • 143 • PS-071 - Are antiangiogenic drugs associated with artery dissections or aneurysms? A global pharmacovigilance study > P. Pernelle Noize • 144 • PS-072 - Role of an academic network in the use and survey of an advanced therapy medicinal product under hospital exemption for adoptive immunotherapy of refractory viral infections > N. Nadine Petitpain • 145 • PS-073 - Migraine: are the actual guidelines properly followed? > E. Elise Van Obberghen-Blanc • 146 • PS-074 - Additional risk factors for bleeding in severe chronic kidney disease patients treated with direct oral anticoagulants > A. Alexandre Gerard • 147 • PS-075 - Safety profile of abiraterone and enzalutamide in the castration-resistant prostate cancer, according to the French Pharmacovigilance database. > L-M. Lucie-Marie Scailteux • 148 • PS-076 - A case of intra-uterine growth retardation with uterine artery doppler abnormality in a context of triptans abuse during pregnancy > D. Delphine Viard-Retur • 149 • PS-077 - Infections after rituximab treatment: mind also the teeth ! > S. Samir Yamani • 15 • PS-010 - Carissa edulis extract, a medicinal plant of Benin pharmacopoeia, induces potent endothelium-dependent relaxation of coronary artery rings involving predominantly nitric oxide > U. Ursula Mawulé Houngue • 150 • PS-078 - Impact of tyrosine-kinase inhibitors on work life in Chronic Myeloid Leukemia : Analysis from the French national health insurance database > C. Cécile Conte • 151 • PS-079 - Acute tubulointerstitial nephritis and checkpoint-inhibitors: are we accusing the wrong suspect? > A. Alexandre Gerard • 152 • PS-080 - Risk of death and cardiac arrest with flecainide, an observational retrospective pharmacovigilance study > G. Guillaume Grenet • 153 • PS-081 - Baclofen for Alcohol Use Disorder: A Systematic review and Meta-Analysis of the randomized clinical trials focusing on Safety Outcomes > M. Marine Auffret • 157 • PS-082 - Patterns of Methylphenidate use and abuse among the overall population: a cluster analysis on health insurance database > E. Elisabeth Frauger • 159 • PS-083 - Antidiabetic drugs errors analysis in Hauts-De-France Region, France > M. Mathieu De Graaf • 162 • PS-084 - Late fetal death after cocaine use in a woman treated with buprenorphine: a case report > E. Emilie Bouquet • 163 • PS-085 - Genomic profiling of BRAFV600mutated metastatic melanoma patients initiating a BRAF inhibitor and MEK inhibitor combined therapy in routine care > B. Baptiste Louveau • 166 • PS-086 - Vigilance of clinical trials: Retrospective analysis of working time and associated costs for a completed study > C. Catherine Mouchel • 167 • PS-087 - What do pregnant women know about Non-steroidal anti-inflammatory drugs (NSAIDs) ? > I. Isabelle Lacroix • 168 • PS-088 - Hemophagocytic lymphohistiocytosis associated with dabrafenib and trametinib combination therapy: about two serious cases > J-L. Jean-Luc Faillie • 169 • PS-089 - Phase I-II open label multicentre study of palbociclib in BRAFV600mut metastatic melanoma patients harbouring CDKN2A loss and RB1 expression and treated with vemurafenib (NCT 02202200) > B. Baptiste Louveau • 170 • PS-090 - Anaphylactic shock induced by Sonovue®: what changes after the removal of the restrictions of use? > A. Annie Pierre Jonville-Bera • 172 • PS-091 - Myocarditis and myositis associated with tocilizumab > J-L. Jean-Luc Faillie • 174 • PS-092 - Evolution of clonazepam abuse and diversion since the application of specific regulations: a proactive addictovigilance surveillance using a multidimensional approach > E. Elisabeth Frauger • 181 • PS-094 - Interstitial lung disease associated with immune checkpoint inhibitors: disproportionality analysis using the World Health Organization’s adverse drug reactions database > P. Pascale Palassin • 185 • PS-095 - Is the risk of acute renal failure similar among proton pump inhibitors? > A. Anaïs Maurier • 187 • PS-096 - Interest of a pharmacovigilance medical consultation: Example of metformin-induced-vitamin B12 deficiency > F. François Montastruc • 188 • PS-097 - AMAFRICA, a patient-navigator program for accompanying lymphoma patients during chemotherapy in Ivory Coast: a prospective randomized study > F. Fabien Despas • 189 • PS-098 - Phenotyping uracil and 5-fluorouracil metabolism using LC-MS/MS to prevent the toxicity of fluoropyrimides > N. Nicolas Picard • 191 • PS-099 - Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by iobitridol (Xenetix®): study of French Pharmacovigilance database > G. Gwenaelle Veyrac • 193 • PS-101 - Implementation of a melanoma tailored next-generation sequencing panel in routine practice > F. Fanélie Jouenne • 194 • PS-102 - Risk mapping of adverse drug reactions for polymedicated nursing home residents > F. Francia Razafy • 197 • PS-104 - Risk of palbociclib-induced neutropenia : check for potential drug interactions! > S. Sophie Fedrizzi • 199 • PS-105 - Inappropriate proton pump inhibitors prescription for polymedicated nursing home residents > F. Francia Razafy • 2 • PS-002 - Vitamin D : « Light on a lack of bulbs » > J. Jean Doucet • 204 • PS-106 - Street drug fraud in Pays de la Loire: seven years of SINTES data analysis > M. Malcolm Barrangou-Poueys • 206 • PS-107 - Results of one year reconciliation activity in Rennes clinical trials vigilance unit > C. Cécile Lefeuvre • 207 • PS-108 - Clinical trials vigilance : comparison of sponsor and investigator's imputabilities of serious adverse events in a randomized, double-blinded study. > C. Catherine Mouchel • 208 • PS-109 - Progress on preclinical PK/Toxicity characterizations of a new squalamine analogue to support the development of a new drug for the prevention of anti-Staphylococcus aureus Surgical Site Infection > O. Olivier Blin • 210 • PS-110 - Clozapine biological monitoring: A study based on data from the French Health Insurance > E. Edouard Laforgue • 211 • PS-111 - Nitrous oxide: alert! > C. Caroline Victorri-Vigneau • 213 • PS-112 - Application and validation of LC-MS/MS bioanalysis of Belimumab in patients with systemic lupus erythematosus. > N. Noël Zahr • 215 • PS-113 - Amoxicillin-induced “dental stains”: a case report and analysis of the French pharmacovigilance database > S. Sophie Fedrizzi • 217 • PS-114 - Pharmacology of a slam session: what risks? > M. Marylène Guerlais • 218 • PS-115 - A case of hepatitis B reactivation after gastric by-pass > L-H. Laure-Hélène Préta • 219 • PS-116 - Drugs in music festivals: Are consumptions the same between different types of music? > M. Marion ISTVAN • 220 • PS-117 - HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine: what about safety in France? > C. Carine JACOMET • 223 • PS-118 - Nationwide quantification of doctor shopping and description of doctor shopper for methylphenidate in France > T. Thomas Soeiro • 227 • PS-120 - Overdose of Ixazomib due to medication error in a clinical trial: two case reports > C. Chloé Fourage • 228 • PS-121 - Therapeutic drug monitoring of three antiepileptic drugs using High Performance Liquid Chromatography with UV-Visible detection > S. Sameh Trabelsi • 230 • PS-122 - UPLC-MS/MS Method For The Simultaneous Quantification Of Ledipasvir, Sofosbuvir And Its Metabolite (GS-331007) In Human Plasma > S. Sameh Trabelsi • 232 • PS-123 - Anagrelide-induced pulmonary hypertension: analysis of national and international pharmacovigilance databases > J. Julie Litovsky • 235 • PS-124 - Aggravation of a myasthenic condition associated with antituberculous drugs: a case with positive rechallenge > J. Julie Litovsky • 236 • PS-125 - Effects of glucocorticoids on sirtuin 1 pathway in rheumatoid arthritis > R. Romain Bordy • 237 • PS-126 - Serious adverse events reporting in clinical trials : is it possible to reduce the background noise ? > L. Lucile Dheyriat • 238 • PS-127 - Evaluation of a questionnaire on requests for emergency contraception in community pharmacies > E. Emilie Jouanjus • 239 • PS-128 - What do general practitioners know about pharmacovigilance? A survey in East-Occitania region. > J-L. Jean-Luc Faillie • 241 • PS-129 - Pregnancy occurence during academic clinical trials from 2009 to 2019 > S. Sophie Duranton • 242 • PS-130 - Kratom (Mitragyna speciosa), mitragynine and 7-hydroxymitragynine are now officially psychotropic substances: the reasons for the new regulation in France > R. Reynald Le Boisselier • 243 • PS-131 - Population Pharmacokinetics Modelling of prescribed factors VIII in patients with severe haemophilia A: toward a global model explaining the main variability of pharmacokinetic parameters > Y. Yoann Cazaubon • 244 • PS-132 - What is the profile of Data Safety Monitoring Board experts? > C. Caroline Serrano • 246 • PS-133 - Data sharing policies of funders of clinical trials in France > F. Florian Naudet • 247 • PS-134 - Safety of P28GST, a protein derived from a schistosome helminth parasite, in patients with Crohn’s disease > C. Céline Leclercq • 248 • PS-135 - Chia seeds (Salvia hispanica) and increased risk of bleeding: a case report > J-L. Jean-Luc Faillie • 249 • PS-136 - New rule in 2017 about codeine prescription: what is the impact for pharmacists? > S. Stéphanie Pain • 25 • PS-013 - Efficacy of BAFF inhibition on features of Sjögren’s syndrome in NOD mice > R. Renaud Felten • 252 • PS-137 - Spontaneous reporting system using a form integrated in the electronic patient record at Montpellier University Hospital: A review of 5 years of experience > V. Virginie Bres • 258 • PS-140 - Cerebrospinal fluid penetration of cefotaxime in pneumococcal meningitis: a multicenter retrospective study > M. Matthieu Grégoire • 259 • PS-141 - In utero exposure to antiretroviral drugs and pregnancy outcomes: secondary analysis of the ANRS pharmacovigilance database from the ANRS-promoted HIV research studies > L. Laura Saint-Lary • 26 • PS-014 - Immunosuppressive agents for Rheumatoid Arthritis: a systematic review of clinical trials and their current development stage > R. Renaud Felten • 262 • PS-142 - Description of CYP3A4*22 and CYP3A5*3 frequencies and impact on first tacrolimus (TAC) doses in renal transplant recipients. > L. Leslie Lori • 263 • PS-143 - Regulation of vascular reactivity by phosphodiesterase-type 2 in mesenteric arteries from rats with heart failure. > B. Boris MANOURY • 266 • PS-144 - Hydroxyurea-Induced Pneumopathy : study in the French Pharmacovigilance Database > S. Sixtine Ginisty • 270 • PS-146 - Underestimated risk of bleeding with concomitant use of ibrutinib and serotonin uptake inhibitors > M. Marion Allouchery • 271 • PS-147 - Clinical trial safety management under the new french legislation, Jardé law : identification of category 2 studies requiring clinical trial safety management. > C. Clémence Poncet • 278 • PS-149 - How to improve expert participation in the Data Safety Monitoring Board of a clinical trial? > T-H. Thi-Huong Nguyen • 279 • PS-150 - Randomized controlled trials using medico-administrative databases: a critical overview > P. Pierre Bourron • 280 • PS-151 - Development and validation of ELISA tests in order to quantify Guselkumab and anti-guselkumab antibodies in psoriasis patients > A. Aurélie Truffot • 281 • PS-152 - Association of ABCB1 and CYP3A5 polymorphism and side effects of Prednisone in giant cell arteritis > V. Venceslas Bourdin • 282 • PS-153 - How to optimize the SAE notification form used in our clinical trials? > M-C. Marie-Caroline Brianceau • 287 • PS-154 - Quantification of human plasma-busulfan concentration by Liquid Chromatography-Tandem Mass Spectrometry > S. Sameh Trabelsi • 288 • PS-155 - Trigger tools to identify adverse drug events in hospitalised children: a systematic review > R. Rama Arab • 289 • PS-156 - Direct conversion from liquid to solid oral forms used in pediatric practice > R. Rama Arab • 294 • PS-157 - Sociodemographic profile of street vendors of medical drugs in Port-au-Prince, Haiti > P. Pascale Emmanuelle Compère • 295 • PS-158 - Evaluation of compliance to antihypertensive therapy among patients of two University hospitals in Port-au-Prince, Haiti > J. Jemima D.a. Olivier • 296 • PS-159 - Placental transfer of betamethasone and severe respiratory distress syndrome in neonates: a population pharmacokinetic analysis > F. Frantz Foissac • 299 • PS-160 - Transplacental transfer of glyburide in women with gestational diabetes and neonatal hypoglycemia risk > H. Hanane Bouchghoul • 3 • PS-003 - Vitamin D in rehabilitation unit : an important concern. > J. Jean Doucet • 30 • PS-015 - Bacterial infections related to intravenous substances abuse > H. Hélène Peyriere • 301 • PS-161 - Deciphering pharmacogenetic-whole blood/intracellular pharmacokinetic-pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients > C. Camille Tron • 302 • PS-162 - Could pharmacogenetics testing explain anthracycline-induced cardiotoxicity sensitivity in hematologic pediatric patients? > C. Camille Tron • 303 • PS-163 - Therapeutic drug monitoring of 5-fluorouracile: a required complementary approach to pre-therapeutic detection of dihydropyrimidine dehydrogenase deficiency to optimize chemotherapy > C. Camille Tron • 310 • PS-164 - Antibiotic prescription in pediatric emergencies department of a general tertiary hospital in Côte d’Ivoire > E. Eric Balayssac • 314 • PS-166 - Economic burden of side effects related to antibiotics: a feasibility study > M-L. Maria-Laura Silva • 318 • PS-167 - Therapeutic drug monitoring of systemic triazole antifungals: a clinical practice review > O. Olivier LE TILLY • 32 • PS-016 - Tacrolimus is a P-glycoprotein but not a Multidrug resistance-associated proteins or a Concentrative nucleoside transporter 3 substrate > F. Florian Lemaitre • 320 • PS-168 - Drug interactions with dietary supplements: a study in the French Pharmacovigilance Database > H. Hélène Peyrouzet • 327 • PS-169 - Medication errors cared for by the Lille’s Poison Control Centre > R. Ramy Azzouz • 330 • PS-170 - Results of a collaboration between a CRPV and an infectious disease care service > S. Soizic Percevault • 331 • PS-171 - Queries related to Complementary and Alternative Medicines and available online data sources: a single pharmacovigilance centre study > H. Hélène Peyrouzet • 334 • PS-172 - Estimated prevalence of exposure to potential drug-drug interactions in France: a retrospective study from 2006 to 2016 > C. Cécile Souty • 335 • PS-173 - Improving adverse drug reaction reporting in Limoges University Hospital: the implementation of a solicited reporting system > H. Hélène Géniaux • 336 • PS-174 - Consistency and complementarity of drug interactions analysis tools used in daily pharmacovigilance practice > H. Hélène Géniaux • 337 • PS-175 - Metronidazole exposure during pregnancy; a systematic review and meta-analysis > P. Priscilla Ajiji • 338 • PS-176 - Comparison of a semi-automated meta-analysis versus conventional meta-analysis; a study protocol > P. Priscilla Ajiji • 340 • PS-178 - Lichenoid eruption during antiPD-L1 immunotherapy with avelumab: a case report from the Prodige 54 trial. > M. Marion Brayer • 341 • PS-179 - Ammonia accidental ingestion in cocaine user: a French case series > R. Romain Torrents • 343 • PS-180 - Real world evidence of drug utilization in patients with lung cancer: a systematic review > A. Andrea Spini • 349 • PS-183 - Cannabinoid Hyperemesis Syndrome in two French emergency departments: a prospective cohort. > R. Romain Torrents • 350 • PS-184 - Paracetamol is a centrally acting analgesic using mechanisms located in the periaqueductal grey > C. Christophe Mallet • 351 • PS-185 - Maternal antidepressant use in pregnancy and major birth defects > L. Laurent Chouchana • 355 • PS-186 - Poisonings with two new antiepileptic drugs: about three cases of lacosamide and one of perampanel overdoses. > R. Romain Torrents • 357 • PS-187 - Paradoxical methemoglobinemia: about a dapsone poisoning case. > J. Julien Reynoard • 359 • PS-188 - Pharmacokinetic-pharmacodynamic profile in patients treated with ceftaroline: a retrospective study > S. Sébastien Lalanne • 360 • PS-189 - Validation of a high performance liquid chromatography‐tandem mass spectrometry method for the quantification of beta-lactams in cardiac valves > S. Sébastien Lalanne • 361 • PS-190 - Heparin induced thrombocytopenia (HIT) without thrombocytopenia: does it exist? > M. Matthieu Colom • 363 • PS-191 - A case report of a therapeutic drug monitoring-guided sofosbuvir-velpatasvir crushed treatment > S. Sébastien Lalanne • 365 • PS-192 - Typologies of medication errors reported to the Pharmacovigilance Regional Centre of Limoges (France) from 2016 to 2018 > M. Muriel Grau • 37 • PS-017 - Rituximab and late onset neutropenia: a French pharmacovigilance database analysis > C. Camille Trouiller • 370 • PS-195 - Modalities of management by Protein kinase inhibitors of incident patients with chronic myeloid leukemia in France > M. Marie Christelle Pajiep Tchapda • 374 • PS-198 - Serious clozapine medication errors in elderly patients: about 3 cases > D. Dorine Fournier • 375 • PS-199 - Exome sequencing allows detection of relevant pharmacogenetic variants in epileptic patients. > S. Simon Verdez • 376 • PS-200 - Delayed thrombocytopenia following Abciximab administration, a pharmacovigilance database study and a review of literature > D. Delphine Bourneau-Martin • 377 • PS-201 - Implementation of model-based therapeutic drug monitoring of vancomycin > R. Romain Garreau • 380 • PS-202 - Interaction caused by rifampicin and rifabutin: quantitative prediction and comparison > M. Mathilde France • 382 • PS-203 - Consumption of psychostimulants and medical students > A. Augustine KAKOU • 385 • PS-204 - Plasma separator tube gels: enemies of the therapeutic drug monitoring of beta-lactams antibiotics by UPLC-PDA? > C. Cyril Leven • 386 • PS-205 - Influence of melanoma cells in endothelial-to-mesenchymal transition > N. Nicolas Clere • 387 • PS-206 - Tramadol: neurological and psychiatric side effects, analysis of reported cases in a university hospital > A. Aurélie Labadie • 389 • PS-207 - Pemetrexed-induced fluid retention: an unusual presentation > A. Anne Dautriche • 390 • PS-208 - Multiple vertebral fractures after denosumab discontinuation > A. Aurore Morel • 392 • PS-209 - Hyponatremia after G5% administration due to medication error: a case series > L. Louise Triquet • 394 • PS-210 - Development and validation of an ex vivo chemosensitivity testing automated method > S. Sarah Ghamrawi • 397 • PS-211 - Is piperacillin-induced DRESS associated with hemophagocytic lymphohistiocytosis (HLH) ? > A. Aurore Gouraud • 399 • PS-212 - Atypical calciphylaxy case in a context of calcic heparin treatment > A-L. Anne-Lise Ruellan • 4 • PS-004 - Pilot study: complete medication review in two units: internal medicine and rheumatology > J. Jean Doucet • 40 • PS-018 - Spontaneous reports from portal of French Ministry of Health versus other reporting ways: are they different? > A. Anne Dautriche • 402 • PS-213 - CAR T cell-related encephalopathy syndrome: about 2 cases > C. Cosette Le Souder • 405 • PS-215 - Pharmacovigilance and adverse drug reactions reporting: dispensing pharmacists’ knowledge and practices in Ille-et-Vilaine (Brittany) > M-N. Marie-Noëlle Osmont • 406 • PS-216 - Description of appropriateness of chronic polypharmacy: a nationwide cohort study > J. Julien Bezin • 41 • PS-019 - Drug allergy in children: the experience of a pharmacovigilance center > F. Frank Rouby • 410 • PS-217 - Use of methylphenidate in the management of binge-eating disorders: two clinical cases > L. Louise Carton • 411 • PS-218 - Effect of Vitis vinifera grape seed extract on motor and sensitive behaviours in an experimental autoimmune encephalomyelitis mouse model > M. Mélina Bégou • 414 • PS-219 - Did mandatory vaccination extension in infants modify the number of spontaneous vaccine adverse reaction reports? > G. Geneviève Durrieu • 415 • PS-220 - Effect of ticagrelor and its active metabolite on the arachidonic acid composition in platelet plasma membrane > J. Jennifer Lagoutte-Renosi • 419 • PS-221 - Drug Monitoring for diagnosis of pharmacobezoar: a case report > M. Manon Launay • 42 • PS-020 - Drug-induced tics: Reviews of the French and world pharmacovigilance databases > F. François Montastruc • 422 • PS-223 - PGxCorpus, a manually annotated corpus for pharmacogenomics > N. Nadine Petitpain • 424 • PS-224 - Opinion, Knowledge and Practice of Prescribing Immunization in Abidjan (Côte d'Ivoire). > J. Jean Claude Yavo • 43 • PS-021 - Antidepressants and Movement Disorders: A Postmarketing Study in the World Pharmacovigilance Database > F. François Montastruc • 431 • PS-225 - Immediate allergy to chlorhexidine: an unrecognized risk. About 10 cases > S. Sylvie Picard • 432 • PS-226 - Posaconazole tablets are administered three times a day in one third of the patients: which impact on through concentrations? > M. Manon Launay • 433 • PS-227 - Medical management of out-of-hours transmissions in a pharmacology laboratory : a description of one year > J. Julien Wils • 436 • PS-228 - Evaluation of the knowledge of intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine in Ivory Coast > J. Jean Claude Yavo • 437 • PS-229 - Interest of a bidisciplinary collaboration: A unique experience of 18th month dermatology-pharmacovigilance consultation > P. Paola Sanchez Pena • 438 • PS-230 - Exposure to gefitinib during pregnancy: a case report > M-A. Marie-Andrée Thompson-Bos • 44 • PS-022 - Risk of Influenza Vaccine-Induced Immune Thrombocytopenia. A Nationwide Population-based Study in France. > M. Margaux Lafaurie • 442 • PS-231 - Glucarpidase in high dose methotrexate delayed elimination: uncertain effectiveness > B. Brahim Azzouz • 443 • PS-232 - Association between gingival and dental pathologies and multiple sclerosis drugs: analysis of the WHO pharmacovigilance database > C. Chloé Fourage • 444 • PS-233 - About a case of Nitrous oxide (N20) induced extensive myelopathy: the wood for the trees ? > R. Reynald Le Boisselier • 446 • PS-234 - Prevalence of chronic pain in opioid-dependent patients using the capture-recapture method: a nationwide population-based study > N. Nicolas Authier • 447 • PS-235 - Preliminary results of an ex vivo chemosensitivity testing assay combining cytarabine to medicinal plant compounds > S. Sarah Ghamrawi • 456 • PS-237 - Serum and peritoneal concentrations after high doses of β-lactams in critically ill patients with severe intra-abdominal infections: a pilot study > E. Elise Pape • 459 • PS-238 - Evaluation of melatonin therapy on improving the metabolic disorders associated to obesity in rats > Y. Youness Kadil • 46 • PS-023 - Who may benefit from diuretics in OSA? A propensity score-matched cohort study > B. Bruno REVOL • 461 • PS-239 - Vitamin D supplementation in patients at risk of osteoporosis: comparison of 2011 and 2019 French guidelines using pharmacokinetic modeling > R. Romain Garreau • 465 • PS-240 - Compliance and tolerance of antiretrovirals in the community > M. Mamadou Kamagaté • 466 • PS-241 - Pharmacokinetics of fluidione and stability of anticoagulant effect > R. Romain Garreau • 467 • PS-242 - Antipsychotics use and weight gain in children compared to adults: analysis of spontaneous adverse drug reaction reports > F. Florentia Kaguelidou • 468 • PS-243 - Impact of learning modalities on performance and motivation in pharmacology practical teaching with animal experimentation: digital vs. traditional support > C. Claire.demiot@unilim.fr Demiot • 47 • PS-024 - Valproic acid and sleep apnea: a disproportionality signal from the WHO pharmacovigilance database > B. Bruno REVOL • 471 • PS-244 - Targeting AML dependency on VCP-mediated DNA repair through a highly selective second generation small molecule inhibitor > L. Lina Benajiba • 475 • PS-246 - Review of 3 years of therapeutic drug monitoring of daptomycin at Rennes University Hospital. > M-C. Marie-Clémence Verdier • 476 • PS-247 - Pre-conception health: survey of women in the Audomaroise region > M. Michaël Rochoy • 48 • PS-025 - Body composition and fat distribution in patients with psoriasis or psoriatic arthritis > E. Eric TOUSSIROT • 49 • PS-026 - Impact of publication bias in the pharmacogenetics of antiepileptic drug’s adverse reactions, a systematic umbrella review and meta-epidemiological study > G. Guillaume Grenet • 52 • PS-027 - Influence of Extracorporeal Membrane Oxygenation on the pharmacokinetics of Ceftolozane/Tazobactam > C. Camille Mané • 53 • PS-028 - Extracorporeal Membrane Oxygenation does not impact the pharmacokinetics of liposomal amphotericin B > C. Camille Mané • 54 • PS-029 - Evaluating prophylactic post cardiac transplantation amphotericin B treatment by simulation > C. Camille Mané • 57 • PS-030 - Drug prescriptions in French pregnant women between 2015 and 2016: a study in the EGB database > I. Isabelle Lacroix • 58 • PS-031 - Myositis associated with Immune Checkpoint Inhibitors: a pharmacovigilance study using the World Health Organization’s adverse drug reactions database > J-L. Jean-Luc Faillie • 60 • PS-032 - Validation and clinical application of a LC-MS/MS method for simultaneous quantification of 4 immunosuppressants using volumetric absorptive microsampling > N. Noël Zahr • 62 • PS-033 - Similar packaging of ZymaD and Zeroverrue: a source of serious administration errors in infants > G. Gabriel Bertoliatti • 63 • PS-034 - Care consumption associated with the use of methylphenidate in children: a cohort study > J-L. Jean-Luc Faillie • 7 • PS-005 - Serious adverse events in the placebo group of trials evaluating systemic treatment in plaque psoriasis > S. Sivem Afach • 76 • PS-036 - Haematologic malignancies associated with clozapine: a pharmacovigilance study in VigiBase® > C. Charles Dolladille • 77 • PS-037 - Fentanyl-transdermal patches: is the potential of abuse the same between the original drug and the generics? > V. Véronique Lelong-Boulouard • 80 • PS-038 - Is cannabis associated with spontaneous pneumothorax? A retrospective descriptive study in a French university hospital > B. Basile CHRETIEN • 82 • PS-039 - Cannabidiol-use in cancerous patients: a growing issue > S. Sophie Fedrizzi • 83 • PS-040 - Why has red yeast rice not the status of medicine in the European Union in 2020? > S. Sophie Fedrizzi • 87 • PS-041 - Formation of investigative teams about Serious Adverse Events reporting in clinical trials: how can we do this ? > M. Marylaure Gavard • 88 • PS-042 - Evaluation of renin-angiotensin system modulators in the treatment of chemotherapy-induced peripheral neuropathies > H. Hichem Bouchenaki • 89 • PS-043 - The HTR4 (rs1345697) genetic polymorphism is associated with lower response after antidepressant treatment in depressed patients: findings from the METADAP cohort > V. Vianney Poinsignon • 93 • PS-044 - Voriconazole and obesity: what dosage adjustment? > C. Christelle Boglione-Kerrien • 95 • PS-045 - Acute kidney injury associated with febuxostat and allopurinol: an analysis of disproportionality based on the global pharmacovigilance database, Vigibase® > A. Amayelle Rey • 98 • PS-046 - Serious adverse effects occurring after chemotherapy: A general cancer registry-based incidence survey > M-C. Marie-Christine Pérault-Pochat • 99 • PS-047 - Levamisole and amphetamine-like adverse drug reactions > M-C. Marie-Christine Pérault-Pochat